A5085296886- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Advanced Radiotherapy Techniques
- Histone Deacetylase Inhibitors Research
- Peptidase Inhibition and Analysis
- Cancer, Stress, Anesthesia, and Immune Response
- Genital Health and Disease
- Lung Cancer Diagnosis and Treatment
- Head and Neck Cancer Studies
- Cancer Diagnosis and Treatment
- Hormonal and reproductive studies
- Synthesis and Catalytic Reactions
- Cancer survivorship and care
- Venous Thromboembolism Diagnosis and Management
- Sexual function and dysfunction studies
- Economic and Financial Impacts of Cancer
- Radiomics and Machine Learning in Medical Imaging
- Management of metastatic bone disease
- Global Cancer Incidence and Screening
- Brain Metastases and Treatment
- Immune cells in cancer
- Urologic and reproductive health conditions
- Effects of Radiation Exposure
- Metabolomics and Mass Spectrometry Studies
- Bladder and Urothelial Cancer Treatments
Georgetown University Medical Center
2016-2024
Georgetown University
2015-2024
Beth Israel Deaconess Medical Center
2020-2024
Harvard University
2020-2024
MedStar Georgetown University Hospital
2014-2024
University of Pennsylvania
2023-2024
Rutgers, The State University of New Jersey
2024
North Carolina Central University
2024
Rutgers Cancer Institute of New Jersey
2024
Case Western Reserve University
2024
Stereotactic body radiotherapy harnesses improvements in technology to allow the completion of a course external beam treatment for prostate cancer span 4 5 sessions. Although mounting short-term data support this approach, long-term outcomes have been sparsely reported.To assess after stereotactic low-risk and intermediate-risk cancer.This cohort study analyzed individual patient from 2142 men enrolled 10 single-institution phase 2 trials multi-institutional between January 1, 2000,...
Abstract Drug resistance in Plasmodium parasites is a constant threat. Novel therapeutics, especially new drug combinations, must be identified at faster rate. In response to the urgent need for antimalarial combinations we screened large collection of approved and investigational drugs, tested 13,910 pairs many promising combinations. The activity known regimens was confirmed myriad classes positively interacting pairings were discovered. Network clustering analyses reinforced established...
Stereotactic body radiation therapy (SBRT) for stage I non-small cell lung cancer (NSCLC) is considered standard of care in the medically inoperable patient population. Multiple methods SBRT delivery exist including fiducial-based tumor tracking, which allows smaller treatment margins and avoidance immobilization devices. We explore long-term clinical outcomes this novel method.In single institutional retrospective review, we detail pathologically confirmed NSCLC. Patients were treated with...
Objective To elucidate the functional erection rate after prostate stereotactic body radiotherapy ( SBRT ) and to develop a comprehensive prognostic model of outcomes treatment. Patients Methods Between 2008 2013, 373 consecutive men with localized cancer were treated at single academic institution as part prospective clinical trial or registry. Prospective longitudinal patient‐reported health‐related quality life HRQ oL) data was collected using Expanded Prostate Cancer Index Composite EPIC...
Abstract Radiotherapy is a curative cancer treatment modality that imparts damage to cellular DNA, induces immunogenic cell death, and activates antitumor immunity. Despite the radiotherapy-induced direct effect seen within treated volume, accumulating evidence indicates activation of innate Acute proinflammatory responses mediated by anticancer M1 macrophages are observed in immediate aftermath following radiotherapy. However, after few days, these converted anti-inflammatory pro-cancer M2...
Local treatment options for patients with in-field non-small cell lung cancer (NSCLC) recurrence following conventionally fractionated external beam radiation therapy (CF-EBRT) are limited. Stereotactic body (SBRT) is a promising modality to achieve reasonable local control, although toxicity remains concern.Patients previously treated high-dose CF-EBRT (≥59.4 Gy, ≤3 Gy/fraction) non-metastatic NSCLC who underwent salvage SBRT localized ultra-central were included in this analysis....
Background: Clinical data suggest that stereotactic body radiation therapy (SBRT) provides similar clinical outcomes as other modalities for prostate cancer. However, reporting on the safety of SBRT after TURP is limited. Herein, we report our experience using to deliver hypofractionated radiotherapy in patients with a history including physician-reported toxicities and patient-reported quality life. Methods: Forty-seven treated from 2007 2016 at Georgetown University Hospital localized...
Abstract Background Ethnicity and insurance status have been shown to impact odds of presenting with metastatic cancer, however, the interaction these two predictors is not well understood. We evaluate difference in disease minorities compared white patients despite access same across three common cancer types. Methods Using National Cancer Database, a multilevel logistic regression model that estimated was fit, adjusting for covariates including year diagnosis, ethnicity, insurance, income,...
We describe the utilization of SpaceOAR Vue™, a new iodinated rectal spacer, during Robotic Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer Patient with contraindication to Magnetic Resonance Imaging. A 69-year-old Caucasian male presented unfavorable intermediate risk prostate cancer and elected undergo SBRT. His medical history was significant atrial fibrillation on Rivaroxaban pacemaker. He felt be at increased radiation proctitis following SBRT due inability accurately...
Purpose Intensity-modulated radiation therapy (IMRT) with brachytherapy boost for unfavorable prostate cancer has been shown to improve biochemical relapse-free survival compared IMRT alone. Stereotactic body (SBRT) is a less-invasive alternative brachytherapy. Early outcomes utilizing SBRT suggest low rates of high-grade toxicity maintained patient-reported quality life. Here, we report the 5-year progression-free (PFS) and cancer-specific (PCSS) patients treated plus boost. Materials...
Background: Patients with a high pretreatment IPSS may have higher rates of late urinary morbidity after radiation therapy for prostate cancer (1). Stereotactic body (SBRT) delivers fewer high-dose fractions radiation, which be radiobiologically favorable to the conventional low-dose external beam fractions. The toxicity associated SBRT, however, remains unclear in patients We report our experience using SBRT localized ≥ 15. Methods: Localized pre-treatment 15 treated at Georgetown...
In patients with localized prostate cancer, 5-fraction, stereotactic body radiation therapy (SBRT) has been found to offer comparable oncologic outcomes and potential for improved treatment compliance compared conventional, 40-plus fraction (RT). Recent studies of patient experiences have highlighted both the impact therapy-associated financial toxicity (FT) on adherence health-related quality life (HRQOL).A cross-sectional assessment FT after SBRT was performed using 12-item COST...
Background: Androgen deprivation therapy (ADT) causes fatigue and sexual dysfunction. The time to testosterone recovery depends on patient treatment-specific characteristics. kinetics of in men treated with neoadjuvant ADT stereotactic body radiotherapy (SBRT) is not well established. This study seeks characterize evaluate its relationship the improvement patient-reported hormonal function. Methods: Institutional review board (IRB) approval was obtained for retrospective prospectively...